Molecular Targeting of Lymphatic Endothelial Receptors for Ligand-directed Imagin

淋巴内皮受体的分子靶向配体定向成像

基本信息

  • 批准号:
    7651588
  • 负责人:
  • 金额:
    $ 20.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-03 至 2011-07-31
  • 项目状态:
    已结题

项目摘要

The lymphatic vasculature plays a critical role in the pathogenesis of many diseases including inflammatory disorders, lymphedema, tumor progression, and metastasis. More recently, the important role of lymphatic vessels in disease states such as tumor dissemination and metastasis has been recognized with the correlation of the number of tumor-associated lymphatic vessels with lymph node metastasis. Discovery and characterization of the lymphatic vessel microenvironment in terms of protein expression levels and their regulatory function will help unravel the specific role lymphatic vessels play in these disease states among others (lymphedema, lymphangioma, tissue repair, inflammation, and psoriatic skin lesions). We have extensive experience with the in vivo selection system in which peptides that home selectively to different tissues are recovered after intravenous administration of a bacteriophage (phage) random peptide library. Here we propose to adapt this selection process and perform an ex vivo phage screening on lymphatic vessels removed during sentinel lymphatic mapping and lymph node biopsy procedures. We may additionally employ several phage display-based approaches to define the cellular and molecular differences that exist in lymphatic channels. These screenings will unveil lymphatic targeting peptides, which will ultimately lead to receptor identification and provide a more complete molecular profile of the lymphatic endothelium and a basis for ligand-directed imaging. We also anticipate that the targeted ligands identified here may be useful in the development of new strategies in the understanding/prevention of metastasis and targeted imaging to monitor the progression of diseases, such as lymphedema. Our Specific Aims are: (i) To isolate lymphatic vessel homing peptides and identify the corresponding lymphatic cell surface receptors and (ii) To evaluate the lymphatic receptor homing capabilities for the design of targeted molecular imaging. We hypothesize that molecular addresses among lymphatic vessels can be exploited for ligand-based imaging of functional and/or diseased lymphatic vessels.
淋巴管系统在许多疾病的发病机制中起着关键作用,包括炎性疾病、淋巴水肿、肿瘤进展和转移。最近,随着肿瘤相关淋巴管的数量与淋巴结转移的相关性,淋巴管在肿瘤扩散和转移等疾病状态中的重要作用已经被认识到。淋巴管微环境在蛋白质表达水平及其调节功能方面的发现和表征将有助于揭示淋巴管在这些疾病状态(淋巴水肿、淋巴管瘤、组织修复、炎症和银屑病皮损)中所起的具体作用。我们在体内选择系统方面有丰富的经验,在体内选择系统中,选择性地归属于不同组织的多肽在静脉注射噬菌体(噬菌体)随机多肽库后被回收。在这里,我们建议调整这一选择过程,并在前哨淋巴标测和淋巴结活检过程中移除的淋巴管上进行体外噬菌体筛选。我们还可以使用几种基于噬菌体展示的方法来定义淋巴通道中存在的细胞和分子差异。这些筛选将揭示淋巴靶向肽,这最终将导致受体识别,并提供更完整的淋巴管内皮细胞分子图谱和配体导向成像的基础。我们还预计,这里确定的靶向配体可能有助于开发新的策略,以了解/预防转移和靶向成像,以监测疾病的进展,如淋巴水肿。我们的具体目标是:(I)分离淋巴管归巢多肽并鉴定相应的淋巴细胞表面受体;(Ii)评估淋巴受体归巢的能力,以设计靶向分子成像。我们假设淋巴管之间的分子地址可以用于基于配体的功能和/或病变淋巴管的成像。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WADIH ARAP其他文献

WADIH ARAP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WADIH ARAP', 18)}}的其他基金

Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10335200
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10553662
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10464889
  • 财政年份:
    2018
  • 资助金额:
    $ 20.1万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    9982236
  • 财政年份:
    2018
  • 资助金额:
    $ 20.1万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10202502
  • 财政年份:
    2018
  • 资助金额:
    $ 20.1万
  • 项目类别:
Targeting Lymphatic Vessels for Ligand Directed Imaging
靶向淋巴管进行配体定向成像
  • 批准号:
    9234681
  • 财政年份:
    2016
  • 资助金额:
    $ 20.1万
  • 项目类别:
Targeting Lymphatic Vessels for Ligand Directed Imaging
靶向淋巴管进行配体定向成像
  • 批准号:
    10049234
  • 财政年份:
    2016
  • 资助金额:
    $ 20.1万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8669059
  • 财政年份:
    2013
  • 资助金额:
    $ 20.1万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8756663
  • 财政年份:
    2013
  • 资助金额:
    $ 20.1万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8271279
  • 财政年份:
    2010
  • 资助金额:
    $ 20.1万
  • 项目类别:

相似海外基金

Collaborative Research: NSF-DFG: CAS: Electrochemical Hydrogenation of Amides and Esters
合作研究:NSF-DFG:CAS:酰胺和酯的电化学氢化
  • 批准号:
    2140205
  • 财政年份:
    2022
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Standard Grant
Collaborative Research: NSF-DFG: CAS: Electrochemical Hydrogenation of Amides and Esters
合作研究:NSF-DFG:CAS:酰胺和酯的电化学氢化
  • 批准号:
    2140196
  • 财政年份:
    2022
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Standard Grant
Atroposelective Synthesis of Hindered Amides - Exploration of Synthetic Peptide Catalysts -
受阻酰胺的天体选择性合成-合成肽催化剂的探索-
  • 批准号:
    504378162
  • 财政年份:
    2022
  • 资助金额:
    $ 20.1万
  • 项目类别:
    WBP Fellowship
Development of Peptide Chemical Modification Enabled by N-Halogenation of Amides
酰胺 N-卤化实现的肽化学修饰的发展
  • 批准号:
    22H02743
  • 财政年份:
    2022
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Modulating Signaling Endocannabinoids and Fatty Acid Amides
调节信号传导内源性大麻素和脂肪酸酰胺
  • 批准号:
    10532252
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
CAREER: SusChEM: Iron Catalysts for the Reduction of Amides
职业:SusChEM:用于还原酰胺的铁催化剂
  • 批准号:
    2146728
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Continuing Grant
Modulating Signaling Endocannabinoids and Fatty Acid Amides
调节信号传导内源性大麻素和脂肪酸酰胺
  • 批准号:
    10399712
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
Nickel-Catalyzed Alpha-Arylation of Secondary Amides
镍催化仲酰胺的α-芳基化
  • 批准号:
    558383-2020
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Canadian Graduate Scholarships Foreign Study Supplements
Function of primary fatty acid amides as lipid mediators
伯脂肪酸酰胺作为脂质介质的功能
  • 批准号:
    20K21285
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Improving selectivity in Ni-catalyzed activation of amides
提高镍催化酰胺活化的选择性
  • 批准号:
    518319-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了